RVx 202
Alternative Names: ProfavaxHSV-2; RVx-202; RVx-202 HSV-2Latest Information Update: 28 Apr 2025
At a glance
- Originator Southern Illinois University School of Medicine; University of Kansas
- Developer Rational Vaccines
- Class Attenuated vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes simplex virus type 2 infections
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in USA (Intradermal)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in USA (Vaginal)
- 30 Mar 2021 Preclinical trials in Herpes simplex virus type 2 infections (Prevention) in USA (Intradermal) before July 2021